Dix ans de progrès en chirurgie des tumeurs de la tête et du cou, quel impact sur la radiothérapie postopératoire ?

Juliette Thariat, E. Babin, Jennifer Le Guévelou(Inserm), M. Humbert(Centre Hospitalier Universitaire de Caen Normandie), B. Géry(Centre François Baclesse), T. Leleu(Centre François Baclesse), Vincent Patron(Centre François Baclesse), Audrey Lasne‐Cardon(Centre François Baclesse), Corinne Jeanne(Centre François Baclesse), Vianney Bastit(Centre François Baclesse), Carmen Florescu(Centre François Baclesse), Emmanuel Micault(Centre François Baclesse)
Bulletin du Cancer
May 26, 2020
10.1016/j.bulcan.2020.04.011
Cited by 6

Related Papers

Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study
|Journal of Clinical Oncology|2013|418
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2021|231
Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement
|International Journal of Radiation Oncology*Biology*Physics|2020|211
Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus
|Radiotherapy and Oncology|2022|98
French consensus regarding precautions during tracheostomy and post-tracheostomy care in the context of COVID-19 pandemic
|European Annals of Otorhinolaryngology Head and Neck Diseases|2020|76